Study of 3 drugs for HER2-low breast cancer that has spread
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (a targeted therapy called chidamide, an immunotherapy called a PD-1 inhibitor, and a drug called anlotinib that blocks blood vessel growth) for people with HER2-low, hormone receptor-positive breast cancer that has spread to other parts of the body or cannot be removed with surgery. It is for those whose cancer has stopped responding to hormone therapy and who have had little or no prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is HER2-low (a specific type based on lab tests) and hormone receptor-positive (HR-positive)
- Your cancer has spread (metastatic) or cannot be surgically removed
- You have tried hormone therapy, but it no longer helps
- You have had 0 or 1 prior chemotherapy treatments for this advanced cancer
- Your tumor tests positive for PD-L1 (a protein that helps cancer hide from the immune system)
- You have at least one measurable tumor that can be seen on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial is testing a combination of two targeted drugs (zanidatamab and tucatinib) plus chemotherapy for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It's for those who have already had at least one other anti-HER2 treatment but no more than three.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.